MEND: Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Sponsor
University of California, San Francisco (Other)
Overall Status
Terminated
CT.gov ID
NCT01939691
Collaborator
Aravind Eye Hospitals, India (Other)
9
3
3
18.6
3
0.2

Study Details

Study Description

Brief Summary

Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to decline. When diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for a long time, it can cause permanent vision loss.

We think that the three eye drop regimens in this study, difluprednate, difluprednate plus nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic macular edema. Patients who enter this study are randomized to one of the three regimens and followed for 24 weeks.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Trial: Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial

Stratification: Systemic corticosteroid/immunosuppressive therapy vs. none

Treatments: 1) difluprednate 0.05% 2) combination therapy of prednisolone acetate 1% with nepafenac 0.1% 3) combination therapy of difluprednate 0.05% with nepafenac 0.1%

Masking: Unmasked treatment administration; masked outcome assessment (evaluation of OCT and visual acuity)

Follow-up: 2, 4, 6, 8, and 24 weeks

Treatment protocol:
Patients will be randomized at enrollment to either:
  • difluprednate 0.05% 4 drops per day

  • prednisolone acetate 1% 4 drops per day and nepafenac 0.1% 3 drops per day

  • difluprednate 0.05% 4 drops per day and nepafenac 0.1% 3 drops per day

If macular edema has not resolved at Week 4, continue study treatment at the same dose until Week 6.

If macular edema has resolved at Week 4, reduce study treatment as follows:
  • difluprednate 0.05% 1 drop per day until Week 6, then stop

  • prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop

  • difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop

If macular edema does not resolve at Week 4 but has resolved at Week 6, reduce study treatment at Week 6 as follows:

  • difluprednate 0.05% 1 drop per day until Week 8, then stop

  • prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop

  • difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop If macular edema resolves at Week 4 but reoccurs at Week 6, treat per best medical judgement.

After Week 8, there are no restrictions on the treatments patients may receive, and medications can be tapered further, discontinued, or changed at the discretion of the treating physician and patient preference. If a patient with previously resolved macular edema has a recurrence, the physician may treat according to best medical judgement.

Study Design

Study Type:
Interventional
Actual Enrollment :
9 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized 3 arm (1:1:1) parallel design comparative effectiveness trialRandomized 3 arm (1:1:1) parallel design comparative effectiveness trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Masked outcome assessment (evaluation of OCT and visual acuity)
Primary Purpose:
Treatment
Official Title:
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
Actual Study Start Date :
Sep 12, 2018
Actual Primary Completion Date :
Mar 31, 2020
Actual Study Completion Date :
Mar 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Difluprednate

Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.

Drug: Difluprednate
Difluprednate 0.05% - corticosteroid eyedrop
Other Names:
  • Durezol
  • Experimental: Nepafenac plus Prednisolone acetate

    Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.

    Drug: Nepafenac
    Nepafenac 0.1% - NSAID eyedrop
    Other Names:
  • Nevanac
  • Drug: Prednisolone acetate
    prednisolone acetate 1% - corticosteroid eyedrop
    Other Names:
  • Pred Forte, Econo Pred
  • Experimental: Difluprednate plus Nepafenac

    Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.

    Drug: Difluprednate
    Difluprednate 0.05% - corticosteroid eyedrop
    Other Names:
  • Durezol
  • Drug: Nepafenac
    Nepafenac 0.1% - NSAID eyedrop
    Other Names:
  • Nevanac
  • Outcome Measures

    Primary Outcome Measures

    1. Central subfield thickness [4 weeks]

      Central subfield thickness measured by spectral domain optical coherence tomography adjusting for baseline thickness

    Secondary Outcome Measures

    1. Resolution [4 weeks]

      proportion of patients with resolution of macular edema

    2. Improvement [4 weeks]

      proportion of patients with improvement in macular edema defined as 20% or greater reduction in central subfield thickness by OCT or resolution of edema

    3. recurrence [4 weeks]

      proportion of patients with recurrence of macular edema defined as greater than 20% increase in central subfield thickness to a value >320 microns by OCT or presence of cysts in an eye that previously had resolution of macular edema

    4. Intraocular pressure (IOP) increase [4 weeks]

      number of patients with intraocular pressure increase at least 10mmHg over baseline

    5. High IOP [4 weeks]

      Number of patients experiencing high intraocular pressure (> 24 mmHg)

    6. Visual acuity [4 weeks]

      best-corrected visual acuity (ETDRS protocol)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    108 patients with uveitic ME will be enrolled at Aravind Eye Hospital in Madurai, India based on the following eligibility criteria:

    Patient-level Inclusion criteria:
    • ≥18 years of age

    • Diagnosis of anterior, intermediate, posterior, or panuveitis (can be infectious or non-infectious)

    • Inactive or minimally active inflammation according to Standardization of Uveitis Nomenclature criteria (≤ 0.5+ Anterior Chamber (AC) cells, ≤ 0.5+ vitreous haze and no active retinal/choroidal lesions)

    • If on oral corticosteroids, a stable dose of <10 mg prednisone/day for >4 weeks

    • If on systemic corticosteroid-sparing immunomodulatory therapy, a stable dose for >4 weeks

    • If using prednisolone acetate 1% drops, stable regimen of ≤2 drops per day for >4 weeks

    • If infectious uveitis, inflammation must be inactive or minimally active per definition above and on stable dose of treatment for ≥4 weeks with no anticipated changes to treatment during the trial

    Eye-level Inclusion Criteria

    • ME defined as thickening of the 1mm central subfield of the macula greater than 2 standard deviations above normal thickness (>320 µm by Heidelberg spectral-domain OCT) with or without the presence of intraretinal cysts.

    • Baseline intraocular pressure >5 mmHg and <21 mmHg (current use ≤3 intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable)

    • Media clarity and pupillary dilation sufficient to allow OCT testing and retinal photography

    • Best-corrected visual acuity of 5/200 or better

    Patient-level Exclusion Criteria

    • Use of oral acetazolamide or other systemic carbonic anhydrase inhibitors at baseline

    • Known allergy or hypersensitivity to any component of the study drugs

    • Women who are pregnant or breastfeeding (pregnancy test should be administered prior to baseline fluorescein angiogram)

    • Patients unwilling or unable to not wear contact lenses during the study period

    • History of central serous chorioretinopathy in either eye

    Eye-level Exclusion Criteria

    • Intravitreal or periocular corticosteroid injection in the past 8 weeks, dexamethasone implant in the past 12 months, or a fluocinolone acetonide implant in the past 3 years

    • Presence of an epiretinal membrane-noted clinically or by OCT-in the study eye, thought to be significant enough to preclude improvement of ME

    • Previous pars plana vitrectomy

    • History of severe glaucoma (C/D ratio > 0.9 or any notching of optic nerve to rim)

    • Prior use of difluprednate or nepafenac in the past 4 weeks

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Aravind Eye Hospital Coimbatore Tamil Nadu India
    2 Aravind Eye Hospital Madurai Tamil Nadu India
    3 Aravind Eye Hospital Pondicherry Tamil Nadu India

    Sponsors and Collaborators

    • University of California, San Francisco
    • Aravind Eye Hospitals, India

    Investigators

    • Principal Investigator: Nisha Acharya, MD MS, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT01939691
    Other Study ID Numbers:
    • 18-24978
    First Posted:
    Sep 11, 2013
    Last Update Posted:
    Jan 13, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of California, San Francisco
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2021